GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress [Yahoo! Finance]
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: Yahoo! Finance
company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38 th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 – 14, where Professor Wieslaw J. Cubala, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, will present long-term clinical data on the safety and efficacy from the open label extension (OLE) of a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201). Additionally, two posters have been accepted presenting safety and tolerability data from the open-label extension part of GH001-TRD-201 as well as data on the psychoactive effects of GH001 in patients with TRD from GH001-TRD-201. “ There remains a substantial unmet medical need for treatment-re
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research (NASDAQ:GHRS) had its price target lowered by analysts at HC Wainwright from $40.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- GH Research (NASDAQ:GHRS) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GHRS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen<MarketBeat
- GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- GH Research Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- AbbVie completes acquisition of Gilgamesh Pharmaceuticals' bretisilocin [Yahoo! Finance]Yahoo! Finance
GHRS
Earnings
- 5/8/25 - Beat
GHRS
Sec Filings
- 11/24/25 - Form 6-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- GHRS's page on the SEC website